🏛️ Verified NIH Record • Updated 2026-08-27

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis (NCT05652335)

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Janssen Research & Development, LLC

🩺 Plain-English Summary (8th-Grade Level)

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).

Who can join: Review the eligibility criteria below.

Location: City of Hope — Duarte, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (29 Sites)

Showing the first 25 of 29 sites.

  • City of Hope — Duarte, California
  • City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
  • University of California San Francisco — San Francisco, California
  • Colorado Blood Cancer Institute — Denver, Colorado
  • Icahn School of Medicine at Mt. Sinai — New York, New York
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • Levine Cancer Institute — Charlotte, North Carolina
  • University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
  • MD Anderson Cancer Center — Houston, Texas
  • UZ Antwerpen — Edegem,
  • UZ Gent — Ghent,
  • CHU de Liege — Liège,
  • CHU Nantes — Nantes,
  • CHU Lyon Sud — Pierre-Bénite,
  • Chu Rennes Hopital Pontchaillou — Rennes,
  • Institut Claudius Regaud — Toulouse,
  • Japanese Red Cross Medical Center — Shibuya City,
  • Osaka University Hospital — Suita-shi,
  • The Cancer Institute Hospital of JFCR — Tokyo,
  • VUMC Amsterdam — Amsterdam,
  • Universitair Medisch Centrum Groningen — Groningen,
  • UMC Utrecht — Utrecht,
  • Hosp. Univ. Germans Trias I Pujol — Badalona,
  • Hosp Clinic de Barcelona — Barcelona,
  • Hosp Univ Fund Jimenez Diaz — Madrid,

📞 Contact the Study Coordinator

Phone: (844) 434-4210

Email: Participate-In-This-Study1@its.jnj.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Relapsed or Refractory Multiple Myeloma

Explore by condition: All Relapsed or Refractory Multiple Myeloma clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗